Evaluation of Soluble PD-1 and PD-L1 in Iraqi Type 2 Diabetes Mellitus (T2DM) Patients with Chronic Toxoplasmosis

Authors

  • Farah E. Mohammed 1, Ali N. Yaseen1 , Muhammed A. H. Aldabagh2

DOI:

https://doi.org/10.37506/mlu.v20i3.1467

Keywords:

Toxoplasma gondii, chronic toxoplasmosis, T2DM, sPD-1 and sPDL-1

Abstract

Toxoplasma gondii is an important opportunistic parasite in immunocompromised people. Globally, diabetes

mellitus is one of the most challenging public health burdens of the 21st century. Both toxoplasmosis and

diabetes are very common in Iraq and other countries. The main objective of the present study was to

investigate the sero- prevalence of the anti-Toxoplasma gondii IgG antibodies in Iraqi T2DM patients and

to clarify the role of soluble programmed death-1 (sPD-1) and ( sPD-L1) in Iraqi T2DM patients with

chronic toxoplasmosis. Enzyme Linked Immunosorbent Assay (ELISA) was used to detect anti- T. gondii

IgG antibodies in the sera of 180 patients with type 2 diabetes mellitus (T2DM) and 163 apparently healthy

controls. The results showed that 117(34%) samples of sera patients have been founded T2DM with

toxoplasmosis, 63(18%) samples have T2DM, 55(16%) cases have control toxoplasmosis (those patients

were had toxoplasmosis but showing no symptoms) and 108 (32%) cases samples were considered as a

control group without any infections. Sera (sPD-1 and sPDL-1) levels were determined by ELISA using a

quantitative sandwich enzyme immunoassay technique. The results showed that levels of sPD-1 and sPDL-1

levels were significantly higher in patients group than healthy subjects (P<0.01).

Author Biography

Farah E. Mohammed 1, Ali N. Yaseen1 , Muhammed A. H. Aldabagh2

1Assist. Prof. , Department of Sciences, College of Basic Education, Mustansiriyah University, Baghdad-Iraq,

2 Assist. Prof., Medical Research Unit, College of Medicine, University of Al-Nahrain. Baghdad-Iraq

Published

2020-07-24

How to Cite

Farah E. Mohammed 1, Ali N. Yaseen1 , Muhammed A. H. Aldabagh2. (2020). Evaluation of Soluble PD-1 and PD-L1 in Iraqi Type 2 Diabetes Mellitus (T2DM) Patients with Chronic Toxoplasmosis. Medico Legal Update, 20(3), 609-615. https://doi.org/10.37506/mlu.v20i3.1467